{"id":"dac","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4204265","moleculeType":"Small molecule","molecularWeight":"698.80"},"_dailymed":{"setId":"81f7c49e-b4da-4815-b66a-67b63193d1dd","title":"GRASS POLLEN (ADRENALINUM, ALLIUM CEPA, ARSENICUM IODATUM, OATS (AVENA SATIVA), BROME GRASS (BROMUS INERMIS), BERMUDA GRASS (CYNODON DACTYLON), ORCHARD GRASS (DACTYLIS GLOMERATA), EUPHRASIA OFFICINALIS, MEADOW GRASS (FESTUCA ELATIOR PRATENSIS), HISTAMINUM HYDROCHLORICUM, PERENNIAL RYE GRASS (LOLIUM PERENNE), TIMOTHY GRASS (PHLEUM PRATENSE), SABADILLA, SANGUINARIA CANADENSIS, RYE GRASS (SECALE CEREALE), JOHNSON GRASS (SORGHUM HALEPENSE), WHEAT GRASS (TRITICUM AESTIVUM), CORN (ZEA MAYS)) LIQUID [NATURALCARE]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAC (decitabine or related cytidine analog) works by inhibiting cytidine deaminase, an enzyme that metabolically inactivates cytarabine and other nucleoside analogs. By blocking this degradation pathway, DAC increases the bioavailability and intracellular concentration of cytarabine, enhancing its anti-leukemic effects. This combination approach is particularly used in hematologic malignancies to improve chemotherapy efficacy.","oneSentence":"DAC is a cytidine deaminase inhibitor that enhances the activity of cytarabine by preventing its inactivation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:28.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (in combination with cytarabine)"},{"name":"Acute lymphoblastic leukemia"}]},"trialDetails":[{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT06661915","phase":"PHASE2","title":"A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-14","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia","enrollment":62},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT04340843","phase":"PHASE2","title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-08","conditions":"Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma","enrollment":19},{"nctId":"NCT05272384","phase":"PHASE1","title":"Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-03","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT06672146","phase":"PHASE2","title":"Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-16","conditions":"Acute Myeloid Leukemia","enrollment":93},{"nctId":"NCT01627041","phase":"PHASE2","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-16","conditions":"Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":178},{"nctId":"NCT07437950","phase":"PHASE2","title":"Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-14","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT03041688","phase":"PHASE1","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-08","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":58},{"nctId":"NCT06577441","phase":"PHASE2","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-12","conditions":"Myelodysplastic Syndrome","enrollment":54},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT05960773","phase":"PHASE2","title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-31","conditions":"Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma","enrollment":9},{"nctId":"NCT07493330","phase":"PHASE1, PHASE2","title":"Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03-23","conditions":"PTCL, Refractory","enrollment":86},{"nctId":"NCT04742634","phase":"PHASE1, PHASE2","title":"Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-05-12","conditions":"Myelodysplastic Syndromes","enrollment":209},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06379360","phase":"PHASE2","title":"Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Acute Myeloid Leukemia","enrollment":77},{"nctId":"NCT05796570","phase":"PHASE2","title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","status":"RECRUITING","sponsor":"Franziska Wachter","startDate":"2023-04-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies","enrollment":37},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05636514","phase":"PHASE1","title":"Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05403762","phase":"NA","title":"Prevention of Incontinence-associated Dermatitis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2022-08-19","conditions":"Incontinence-associated Dermatitis","enrollment":220},{"nctId":"NCT07472322","phase":"PHASE1, PHASE2","title":"ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV","enrollment":31},{"nctId":"NCT06484062","phase":"PHASE1","title":"Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT06561074","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-25","conditions":"T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma","enrollment":22},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT07466394","phase":"NA","title":"COGSCREEN II: Early Detection of Cognitive Impairment","status":"RECRUITING","sponsor":"Robert Perneczky","startDate":"2025-06-01","conditions":"Alzheimer's Disease (AD)","enrollment":400},{"nctId":"NCT04746235","phase":"PHASE2","title":"Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT06401603","phase":"PHASE1","title":"A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-06","conditions":"Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06930651","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-03","conditions":"Myeloid Malignancies","enrollment":42},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03502668","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2018-07-27","conditions":"Myelodysplastic Syndromes","enrollment":160},{"nctId":"NCT04953897","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-12-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":18},{"nctId":"NCT04953910","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2022-12-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":27},{"nctId":"NCT03404193","phase":"PHASE2","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":235},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT03969446","phase":"PHASE1","title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT03844815","phase":"PHASE1","title":"Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-18","conditions":"Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm","enrollment":27},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT06847542","phase":"PHASE3","title":"A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":250},{"nctId":"NCT07437170","phase":"PHASE2","title":"Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT06511882","phase":"PHASE2","title":"Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-07","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT03358719","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-03-27","conditions":"Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":8},{"nctId":"NCT07435636","phase":"PHASE2","title":"Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis","status":"NOT_YET_RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2026-04-13","conditions":"Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis","enrollment":80},{"nctId":"NCT03974217","phase":"PHASE1","title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-08-01","conditions":"Leukemia","enrollment":13},{"nctId":"NCT06297629","phase":"PHASE2","title":"A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-01","conditions":"Allogeneic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT04061421","phase":"PHASE1, PHASE2","title":"Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)","status":"RECRUITING","sponsor":"Michael Savona","startDate":"2021-11-24","conditions":"MDS/MPN","enrollment":94},{"nctId":"NCT05403450","phase":"PHASE1","title":"A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-02-22","conditions":"Relapsed/Refractory Peripheral T-cell Lymphoma","enrollment":33},{"nctId":"NCT07177079","phase":"PHASE1","title":"High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Kittika Poonsombudlert","startDate":"2026-05-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT07420790","phase":"","title":"Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2026-02","conditions":"Acute Myeloid Leukemia","enrollment":1941},{"nctId":"NCT05010122","phase":"PHASE1, PHASE2","title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT05007873","phase":"PHASE2","title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":70},{"nctId":"NCT06191978","phase":"PHASE1","title":"A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-07","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT04655755","phase":"PHASE1, PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-19","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT03445858","phase":"EARLY_PHASE1","title":"Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-02-12","conditions":"Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer","enrollment":22},{"nctId":"NCT06284460","phase":"PHASE1, PHASE2","title":"Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-31","conditions":"Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm","enrollment":""},{"nctId":"NCT04854889","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-04-22","conditions":"Refractory Aplastic Anemia","enrollment":3},{"nctId":"NCT07231289","phase":"NA","title":"Effect of Soundscapes on Emotional Distress in Fibromyalgia: a 4×4 Crossover Trial","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2025-11-24","conditions":"Fibromyalgia Syndrome","enrollment":72},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT04872543","phase":"PHASE2","title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-29","conditions":"Malignant Peripheral Nerve Sheath Tumors (MPNST)","enrollment":25},{"nctId":"NCT06712121","phase":"PHASE2","title":"Venetoclax and Decitabine in R/R T-ALL","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-01-30","conditions":"T Lymphoblastic Leukemia/Lymphoma","enrollment":28},{"nctId":"NCT06177171","phase":"PHASE1","title":"Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors","status":"RECRUITING","sponsor":"Pamela Munster","startDate":"2024-02-07","conditions":"BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation","enrollment":18},{"nctId":"NCT06091267","phase":"PHASE1, PHASE2","title":"PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Beijing Research Institute","startDate":"2023-10-16","conditions":"Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT05455294","phase":"PHASE1","title":"Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2022-07-18","conditions":"Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis","enrollment":16},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT06997094","phase":"PHASE1","title":"Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-23","conditions":"Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT05230368","phase":"PHASE1","title":"Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-12-14","conditions":"HIV-1-infection, Subtype b","enrollment":9},{"nctId":"NCT02961101","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies","status":"RECRUITING","sponsor":"Han weidong","startDate":"2016-05","conditions":"Malignancies Multiple","enrollment":250},{"nctId":"NCT03679650","phase":"PHASE1","title":"Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-10-11","conditions":"Acute Myelogenous Leukemia","enrollment":28},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT05038592","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-04","conditions":"Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":64},{"nctId":"NCT07348575","phase":"PHASE3","title":"A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-07-01","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":80},{"nctId":"NCT07006025","phase":"PHASE1","title":"A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Treebough Therapies","startDate":"2025-06-03","conditions":"MDS","enrollment":20},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT03946670","phase":"PHASE2","title":"A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Myelodysplastic Syndromes","enrollment":127},{"nctId":"NCT03875287","phase":"PHASE1","title":"Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-17","conditions":"Solid Tumor","enrollment":35},{"nctId":"NCT03661307","phase":"PHASE1, PHASE2","title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-31","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":73},{"nctId":"NCT04874480","phase":"PHASE1","title":"Tegavivint for the Treatment of Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-27","conditions":"Recurrent Leukemia, Refractory Leukemia","enrollment":9},{"nctId":"NCT05799079","phase":"PHASE2","title":"Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant","status":"TERMINATED","sponsor":"Sanjay Mohan","startDate":"2023-04-13","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT06327685","phase":"PHASE1","title":"Avapritinib With Decitabine in Patients With SM-AHN","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-13","conditions":"Systemic Mastocytosis With an Associated Hematologic Neoplasm","enrollment":34},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT07318662","phase":"","title":"Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-01-01","conditions":"MDS, CMML","enrollment":224},{"nctId":"NCT05184842","phase":"PHASE2","title":"Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-03-23","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":91},{"nctId":"NCT06393361","phase":"PHASE2","title":"Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-06-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT05405114","phase":"PHASE2","title":"Research Study Investigating How Well NDec Works in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-07-07","conditions":"Sickle Cell Disease","enrollment":96},{"nctId":"NCT06291285","phase":"PHASE1","title":"A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-27","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT03613532","phase":"PHASE1","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2018-10-24","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":102},{"nctId":"NCT04245397","phase":"PHASE1","title":"Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2020-06-30","conditions":"Myelodysplastic Syndromes","enrollment":151},{"nctId":"NCT06383572","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-26","conditions":"Lymphodepleting Chemotherapy, Myeloid Malignancies","enrollment":44},{"nctId":"NCT06232655","phase":"PHASE2","title":"Cladribine Venetoclax in Monocytic AML","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT03922555","phase":"PHASE1","title":"ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-07-12","conditions":"Neurological Cancer","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"PAIN"},{"count":10,"reaction":"ANXIETY"},{"count":8,"reaction":"FATIGUE"},{"count":8,"reaction":"NAUSEA"},{"count":8,"reaction":"PULMONARY EMBOLISM"},{"count":7,"reaction":"EMOTIONAL DISTRESS"},{"count":7,"reaction":"FALL"},{"count":7,"reaction":"PNEUMONIA"},{"count":6,"reaction":"DEATH"},{"count":6,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":3322,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- Cladribine","- Cytosine arabinoside [Ara-C]","- Daunorubicin"],"phase":"marketed","status":"active","brandName":"DAC","genericName":"DAC","companyName":"dr hab. n. med. Agnieszka Wierzbowska","companyId":"dr-hab-n-med-agnieszka-wierzbowska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAC is a cytidine deaminase inhibitor that enhances the activity of cytarabine by preventing its inactivation. Used for Acute myeloid leukemia (in combination with cytarabine), Acute lymphoblastic leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}